A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC

Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC'. Together they form a unique fingerprint.

Medicine & Life Sciences